

Contents

1	Introduction.....	1
	<i>Wayne R. Gombotz and Steven J. Shire</i>	
Part I Design Of Therapeutic MABS		
2	CDR Repair: A Novel Approach to Antibody Humanization	9
	<i>Mark S. Dennis</i>	
3	Nanobodies, Single-Domain Antigen-Binding Fragments of Camelid Heavy-Chain Antibodies	29
	<i>Gholamreza Hassanzadeh Ghassabeh, Serge Muyldermans, and Dirk Saerens</i>	
Part II Expression and Production of MABS		
4	GPEX® A Flexible Method for the Rapid Generation of Stable, High Expressing, Antibody Producing Mammalian Cell Lines	51
	<i>Gregory T. Bleck</i>	
5	Advancing Our Cell Culture Platform: Incorporating Lessons Learned and New Technologies	63
	<i>Carole Heath</i>	
Part III Recovery and Purification		
6.	Addressing Changes Associated with Technology Transfer: A Case Study.....	75
	<i>Michele M. Myers, Camille Keating, Joann Bannon, Donald S. Neblock, and Peter W. Wojciechowski</i>	
7	Concepts for Disposables in Biopharmaceutical Manufacture	87
	<i>Joachim K. Walter and Uwe Gottschalk</i>	
Part IV Formulation and Delivery		
8	Formulation and Delivery Issues for Monoclonal Antibody Therapeutics.....	103
	<i>Ann L. Daugherty and Randall J. Mrsny</i>	

9	Challenges in the Development of High Protein Concentration Formulations.....	131
	<i>Steven J. Shire, Zahra Shahrokh, and Jun Liu</i>	
10	Protein Immobilization by Crystallization and Precipitation: An Alternative to Lyophilization	149
	<i>Karoline Bechtold-Peters</i>	
Part V Analytics and Specification Setting for MABS		
11	Characterizing High Affinity Antigen/Antibody Complexes by Kinetic and Equilibrium Based Methods.....	179
	<i>Andrew W. Drake, David G. Myszka, and Scott L. Klakamp</i>	
12	Analytical Characterization of Monoclonal Antibodies: Linking Structure to Function.....	193
	<i>Reed J. Harris, Edward T. Chin, Frank Macchi, Rodney G. Keck, Bao-Jen Shyong, Victor T. Ling, Armando J. Cordoba, Melinda Marian, Don Sinclair, John E. Battersby, and Andy J.S. Jones</i>	
13	Analysis of Irreversible Aggregation, Reversible Self-association and Fragmentation of Monoclonal Antibodies by Analytical Ultracentrifugation.....	207
	<i>James D. Andya, Jun Liu, and Steven J. Shire</i>	
14	Biophysical Signatures of Monoclonal Antibodies	229
	<i>N. Harn, T. Spitznagel, M. Perkins, C. Allan, S. Shire, and C. R. Middaugh</i>	
Part VI Pharmacokinetics and Immunogenicity		
15	Impact of Fc Glycosylation on Monoclonal Antibody Effector Functions and Degradation by Proteases.....	249
	<i>T. Shantha Raju</i>	
16	Immunogenicity Assessment of Antibody Therapeutics	271
	<i>P. Stas, Y. Gansemans, and I. Lasters</i>	
Part VII Armed Antibodies and New Classes of Antibodies		
17	Production of Monoclonal Antibodies in <i>E. coli</i>	295
	<i>Dorothea E. Reilly and Daniel G. Yansura</i>	
18	Recent Advancements in the Use of Antibody Drug Conjugates for Cancer Therapy	309
	<i>Peter D. Senter</i>	
19	Antibody Radiolabeling.....	323
	<i>Corinne Bensimon and Russell Redshaw</i>	
	Index	345

<http://www.springer.com/978-0-387-76642-3>

Current Trends in Monoclonal Antibody Development
and Manufacturing

Shire, S.J.; Gombotz, W.; Bechtold-Peters, K.; Andya, J.
(Eds.)

2010, XIV, 354 p., Hardcover

ISBN: 978-0-387-76642-3